Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL686437 | 0.92 | PTPRB (0.74) | PTPRBPTPN1 | |
| SCHEMBL686936 | 0.88 | PTPRB (0.75) | PTPRBPTPN1 | |
| SCHEMBL679689 | 0.85 | PTPRB (1.00) | PTPRB | |
| SCHEMBL679690 | 0.85 | PTPRB (1.00) | PTPRB | |
| SCHEMBL686529 | 0.84 | PTPRB (0.75) | PTPRB | |
| SCHEMBL3571611 | 0.83 | PTPRB (1.00) | PTPRB | |
| SCHEMBL684532 | 0.83 | PTPRB (1.00) | PTPRB | |
| SCHEMBL28841279 | 0.80 | PTPRB (0.74) | PTPRB | |
| SCHEMBL14652334 | 0.79 | PTPRB (0.76) | PTPRBPTPN1 | |
| SCHEMBL1709745 | 0.79 | PTPRB (0.76) | PTPRBPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | PTPRB 1894/4885PTPN1 885/4885 |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885PTPN1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.